UNITED LAB: Injection UBT37034 for overweight or obesity indications has received clinical trial implied approval
UNITED LAB announced that its wholly-owned subsidiary, UNITED BIOTECH (Zhuhai Hengqin) Co., Ltd., has obtained the implied approval from the National Medical Products Administration of China for the clinical trial of UBT37034 injection targeting overweight or obesity. This drug is a novel peptide receptor agonist that can reduce weight by selectively acting on the neuropeptide Y2 receptor. The clinical trial application for UBT37034 was approved by the U.S. FDA in July 2025. The company will continue to focus on the research and development of new products to enhance its competitiveness in the biopharmaceutical industry
According to the Zhitong Finance APP, UNITED LAB (03933) announced that on September 29, 2025, its wholly-owned subsidiary, UNITED LAB Biotech (Zhuhai Hengqin) Co., Ltd., received the implied approval for the clinical trial registration application of its self-developed Class 1 innovative drug injectable UBT37034 for the indication of overweight or obesity from the National Medical Products Administration of China, with acceptance number CXHL2500772.
UBT37034 is a novel peptide receptor agonist that can reduce weight by selectively acting on the neuropeptide Y2 receptor. Preclinical studies in various animal models have shown that UBT37034 can significantly reduce weight when used in combination with GLP-1 analogs. In addition, the new drug clinical trial application (IND) for UBT37034 injectable solution for the indication of overweight or obesity was approved by the U.S. Food and Drug Administration in July 2025, with IND number 175188.
In the future, the company will continue to focus on the research and development of new products and enhance its competitiveness and creativity in the biopharmaceutical industry, expecting to create greater returns for the company and its shareholders
